Cluster of differentiation 96 as a leukemia stem cell-specific marker and a factor for prognosis evaluation in leukemia
Cluster of differentiation 96 as a leukemia stem cell-specific marker and a factor for prognosis evaluation in leukemia
复制标题
DOI：
10.3892/mco.2015.552
复制
发表时间：
2015-07-01
影响因子：
1.2
通讯作者：
Zheng, Jin'e
中科院分区：
文献类型：
--
作者：
Du, Wen;Hu, Yanjie;Zheng, Jin'e
对化疗的耐药性是白血病治疗的主要挑战。白血病干细胞（LSC）是一小部分具有自我更新能力的白血病细胞，在化疗耐药性的形成中起着重要作用。应用流式细胞术检测了105例急性白血病（AL）患者外周血CD 34（+）CD 38（-）细胞分化抗原96（CD 96）的表达。结果表明，AL患者CD 34（+）、CD 34（+）、CD 38（-）、CD 34（+）、CD 38（-）、CD 96（+）细胞比例均明显高于正常对照组（P <15%的CD 34（+）CD 38（-）细胞达到完全缓解（CR），表明作为富含LSC的群体，CD 34（+）CD 38（-）细胞的数量可能与难治性LSC的比例无关。CD 96自身阳性率在CR组与非CR组间无显著性差异（P>0.05）。然而，在AML人群中CR率显著较高，
Resistance to chemotherapy is a major challenge for leukemia treatment. It has been suggested that leukemia stem cells (LSCs), a small pool of self-renewing leukemic cells, play important roles in development of chemotherapy resistance. The expression of cluster of differentiation 96 (CD96), a potential marker for LSCs, was investigated in CD34(+)CD38(-) cells of 105 acute leukemia (AL) patients by flow cytometry. The data showed that all the CD34(+), CD34(+) CD38(-) and CD34(+) CD38(-)CD96(+) proportions were much higher in AL compared to the normal control (P15% CD34(+)CD38(-) cells achieved complete remission (CR), suggesting that as an LSC-rich population, the amount of CD34(+)CD38(-) cells may not be positively associated with the proportion of refractory LSCs. The mean percentage of the co-presence of CD96 expression itself was similar in AML patients with CR and non-CR (P>0.05). However, the CR rate was significantly higher in the AML population with